Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00015834 · ClinicalTrials.gov registry record · Phase 1
STI571 Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia
A Phase 1 study of Chronic Myelogenous Leukemia, BCR-ABL1 Positive and Blastic Phase Chronic Myelogenous Leukemia, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
- 1
- Study location
NCT00015834 is a Phase 1 study of Chronic Myelogenous Leukemia, BCR-ABL1 Positive and Blastic Phase Chronic Myelogenous Leukemia that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 46 participants, above the 42-participant average among 10 other Chronic Myelogenous Leukemia, BCR-ABL1 Positive trials with a reported enrollment target (10% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00015834, a Phase 1 study of Chronic Myelogenous Leukemia, BCR-ABL1 Positive and Blastic Phase Chronic Myelogenous Leukemia, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
- 1
- Study location
Study Summary
Phase I/II trial to study the effectiveness of combining STI571 and chemotherapy in treating patients who have chronic myelogenous leukemia. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. STI571 may stop the growth of leukemia cells. Combining chemotherapy and STI571 may kill more cancer cells
Conditions Studied
Interventions
- DRUG imatinib mesylate
- DRUG cytarabine
Study Locations (1)
California
- University of California at Los Angeles (UCLA ) - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2001-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00015834
The ClinicalTrials.gov registry entry for NCT00015834 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 42-participant average among 10 other Chronic Myelogenous Leukemia, BCR-ABL1 Positive trials with a reported enrollment target (10% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Chronic Myelogenous Leukemia, BCR-ABL1 Positive appearing as the primary indexed condition, and to 2 interventions - of which imatinib mesylate is the first listed.
NCT00015834 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00015834 about?
NCT00015834 is a clinical study titled "STI571 Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia". Phase I/II trial to study the effectiveness of combining STI571 and chemotherapy in treating patients who have chronic myelogenous leukemia. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. STI571 may stop the growth of leukemia cells. Com...
What is the current status of trial NCT00015834?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2001-05.
What conditions does trial NCT00015834 study?
This clinical trial studies the following conditions: Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Blastic Phase Chronic Myelogenous Leukemia, Relapsing Chronic Myelogenous Leukemia.
What interventions are being tested in trial NCT00015834?
The interventions under investigation include: imatinib mesylate (DRUG), cytarabine (DRUG).
Who is sponsoring clinical trial NCT00015834?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00015834 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
RECRUITING · Phase 1
-
Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant
ACTIVE NOT RECRUITING · Phase 1
-
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
COMPLETED · Phase 1
-
Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases
COMPLETED · Phase 1
-
Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes
ACTIVE NOT RECRUITING · Phase 2
-
Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study
ACTIVE NOT RECRUITING · NA
Explore more on PlainTrial
Chronic Myelogenous Leukemia, BCR-ABL1 Positive
All registered trials for this condition
Blastic Phase Chronic Myelogenous Leukemia
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.